OSE Pharma SA (OSE) fair value: what the stock is really worth
We calculate from audited financials what OSE Pharma SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 16, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch OSE Pharma SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range €2.46 – €13.16 · fair‑value band €0.5800 – €1.16 · the €2.46 price screens above the €0.7700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Jul 16, 2026.
Follow OSE Pharma in your weekly email
Every Wednesday you see whether OSE Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Show more
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Stock analysis
OSE Pharma SA (OSE) currently trades at €2.46, while our model-based Fair Value estimate is €0.7700, implying the stock looks roughly 219.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: €0.5800 (bear) to €1.16 (bull), the price of €2.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
OSE Pharma SA reported revenue of €2.6M in FY2025 versus €26.3M in FY2021, a compound −43.9%/yr. Reported net income was −€37.7M in FY2025.
Key figures
Market cap €78.6M · P/S ratio 29.2 · EPS (TTM) €−1.69 · Return on equity −82.3% · Return on assets (EBIT) −16.6% · Operating margin −2,272% · Revenue (TTM) €2.7M · Revenue growth (YoY) −0.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −69%, OSE screens richer than that median.
Fair Value models
Bear €0.5800Fair Value €0.7700Bull €1.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−96.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−47.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.2%
Start year 2020 (pandemic). Over 10 years: +91.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.1%
’15
’16
’17
’18
’19
’20
’21
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−182.3% (2020) → −1,615.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside−70% · Below median
Profitability
Return on assets−23% · Below median
Growth and dividend
Revenue growth−1% · Below median
Balance sheet
Debt / equity0.80× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.27× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)33.23× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)60· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "OSE Pharma SA Fair Value". https://www.fairvalue-calculator.com/stock/OSE
Frequently asked questions
Is OSE Pharma SA (OSE) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of €0.7700 versus a price of €2.46, about −69% upside (overvalued).
What is the fair value of OSE?
Our model-based fair value for OSE Pharma SA is €0.7700 (as of Jul 16, 2026), built from audited fundamentals. The current price: €2.46.
What is the quality score of OSE?
OSE Pharma SA has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OSE Pharma SA (OSE)?
Our model-based price target is the fair value of €0.7700 (as of Jul 16, 2026) from 1 valuation models. Cautious scenario €0.5800, optimistic scenario €1.16. It is a calculation from audited fundamentals, not an analyst target.
What is the OSE Pharma SA stock forecast for 2026?
Our models put fair value at €0.7700, about −69% upside versus a price of €2.46 (overvalued). Cautious scenario €0.5800, optimistic scenario €1.16. The calculation is refreshed regularly with new filings.
What is the revenue of OSE Pharma SA (OSE)?
OSE Pharma SA reported trailing-twelve-month revenue of about €2.7M (latest available figure, as of Jul 16, 2026).
What is the intrinsic value of OSE Pharma SA (OSE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OSE Pharma SA it is €0.7700 per share (as of Jul 16, 2026), against a price of €2.46. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is OSE Pharma SA stock overvalued or undervalued in 2026?
As of Jul 16, 2026, OSE trades above its calculated fair value: price €2.46, fair value €0.7700, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OSE?
No. The price is what the market pays today (€2.46); the fair value is what the company's own numbers justify (€0.7700). For OSE Pharma SA the two are €1.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is OSE Pharma SA worth?
The market values OSE Pharma SA at about €78.6M (market capitalisation, as of Jul 16, 2026). Per share that is €2.46; our models calculate a fair value of €0.7700 per share.
What do the bullish and bearish scenarios say about OSE?
Our models span a range for OSE Pharma SA: cautious scenario €0.5800, base €0.7700, optimistic €1.16 per share (as of Jul 16, 2026, price €2.46). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OSE Pharma SA (OSE)?
Balance-sheet figures for OSE Pharma SA (as of Jul 16, 2026): return on equity −82.3%, debt of 0.80 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is OSE from its 52-week high?
OSE Pharma SA trades at €2.46, about 66% below its 52-week high of €7.20 and at the low of €2.46 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.7700 is for.
Which stocks are comparable to OSE Pharma SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OSE Pharma SA stock attractive at the current price?
The data as of Jul 16, 2026: price €2.46, calculated fair value €0.7700 (−69%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OSE calculated?
We run OSE Pharma SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.7700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. OSE Pharma SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OSE Pharma SA (OSE)?
The closing price on Sep 24, 2026 was €2.46. Our model-based fair value is €0.7700, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OSE Pharma SA right now?
The price sits above even our optimistic bull case (€1.16). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.5800 to €1.16) leaves room in how you read the outcome.
Key figures of OSE Pharma SA
How large is the market capitalisation of OSE Pharma SA (OSE)?
The market capitalisation of OSE Pharma SA is €78.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OSE Pharma SA (OSE)?
The price-to-sales ratio of OSE Pharma SA is 29.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OSE Pharma SA (OSE)?
Earnings per share at OSE Pharma SA are €−1.69. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of OSE Pharma SA (OSE)?
The return on equity (ROE) of OSE Pharma SA is −82.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OSE Pharma SA (OSE)?
On an EBIT basis the return on assets of OSE Pharma SA is −16.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OSE Pharma SA (OSE)?
The operating margin of OSE Pharma SA is −2,272% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OSE Pharma SA (OSE)?
Revenue at OSE Pharma SA is growing −0.8% versus a year earlier (3y avg −47.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OSE Pharma SA (OSE)?
Earnings per share at OSE Pharma SA are growing −95.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does OSE Pharma SA (OSE) generate?
The free cash flow of OSE Pharma SA is −€34.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does OSE Pharma SA (OSE) carry?
The net debt of OSE Pharma SA is €17.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch OSE Pharma SA in the live analysis
One click puts OSE Pharma SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
